JP2019532011A - Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ - Google Patents

Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ Download PDF

Info

Publication number
JP2019532011A
JP2019532011A JP2018506309A JP2018506309A JP2019532011A JP 2019532011 A JP2019532011 A JP 2019532011A JP 2018506309 A JP2018506309 A JP 2018506309A JP 2018506309 A JP2018506309 A JP 2018506309A JP 2019532011 A JP2019532011 A JP 2019532011A
Authority
JP
Japan
Prior art keywords
cancer
flt3
patient
chromosomal
cleanolib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532011A5 (enExample
Inventor
ビナイ・ケイ・ジャイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019532011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Publication of JP2019532011A publication Critical patent/JP2019532011A/ja
Publication of JP2019532011A5 publication Critical patent/JP2019532011A5/ja
Priority to JP2022031616A priority Critical patent/JP7536320B2/ja
Priority to JP2024064106A priority patent/JP2024096859A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018506309A 2016-11-02 2017-10-31 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ Pending JP2019532011A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022031616A JP7536320B2 (ja) 2016-11-02 2022-03-02 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2024064106A JP2024096859A (ja) 2016-11-02 2024-04-11 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
US62/416,475 2016-11-02
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
PCT/US2017/059377 WO2018085292A1 (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations
US15/799,684 2017-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022031616A Division JP7536320B2 (ja) 2016-11-02 2022-03-02 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ

Publications (2)

Publication Number Publication Date
JP2019532011A true JP2019532011A (ja) 2019-11-07
JP2019532011A5 JP2019532011A5 (enExample) 2020-06-25

Family

ID=62020370

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018506309A Pending JP2019532011A (ja) 2016-11-02 2017-10-31 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2022031616A Active JP7536320B2 (ja) 2016-11-02 2022-03-02 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2024064106A Withdrawn JP2024096859A (ja) 2016-11-02 2024-04-11 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022031616A Active JP7536320B2 (ja) 2016-11-02 2022-03-02 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2024064106A Withdrawn JP2024096859A (ja) 2016-11-02 2024-04-11 Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ

Country Status (19)

Country Link
US (3) US11078541B2 (enExample)
EP (1) EP3359155A4 (enExample)
JP (3) JP2019532011A (enExample)
KR (2) KR20180074792A (enExample)
CN (1) CN108778276A (enExample)
AU (1) AU2017353925A1 (enExample)
BR (1) BR112019008762A2 (enExample)
CA (1) CA3024012A1 (enExample)
CL (1) CL2019001208A1 (enExample)
CO (1) CO2019005466A2 (enExample)
EA (1) EA201991078A1 (enExample)
HK (1) HK1257195A1 (enExample)
IL (1) IL266303A (enExample)
MX (1) MX2019005008A (enExample)
PE (1) PE20191238A1 (enExample)
PH (1) PH12019500965A1 (enExample)
SG (1) SG11201903889TA (enExample)
WO (1) WO2018085292A1 (enExample)
ZA (1) ZA201903089B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022071099A (ja) * 2016-11-02 2022-05-13 アログ・ファーマシューティカルズ・インコーポレイテッド Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ
JP2023536068A (ja) * 2020-07-20 2023-08-23 アログ・ファーマシューティカルズ・インコーポレイテッド クレノラニブの結晶形態およびそれを用いる方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US12662706B2 (en) 2016-11-02 2026-06-23 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US12268690B2 (en) 2018-07-27 2025-04-08 Oregon Health & Science University Treatments for mutations in acute myeloid leukemia
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (zh) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 一种hyml-122血药浓度定量分析方法
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (zh) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180639A (ja) * 2009-04-06 2015-10-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｋｃｎｑ１遺伝子の多型に基づいた治療方法
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
DK1641780T3 (da) 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
CN104508143A (zh) * 2012-03-12 2015-04-08 纪念斯隆-凯特琳癌症中心 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
KR20180074792A (ko) * 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180639A (ja) * 2009-04-06 2015-10-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｋｃｎｑ１遺伝子の多型に基づいた治療方法
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Abstract 3660: Crenolanib: A next generation FLT3 inhibitor", AACR; CANCER RES, vol. Vol.72, Suppl.8, JPN6021011788, 2012, pages 3660, ISSN: 0004476996 *
"SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDAR", EHA LEARNING CENTER, JPN6021011785, 10 June 2016 (2016-06-10), ISSN: 0004630656 *
ANNALS OF CLINICAL AND LABORATORY SCIENCE, vol. 45, no. 5, JPN6021011793, 2015, pages 515 - 521, ISSN: 0004476998 *
BLOOD REVIEWS, vol. 31, no. 2, JPN6021011794, 8 October 2016 (2016-10-08), pages 43 - 62, ISSN: 0004476999 *
BLOOD, vol. 124, no. 21, JPN6021011784, 2014, pages 389, ISSN: 0004630655 *
BLOOD, vol. 124, no. 21, JPN6021011790, 2014, pages 2333, ISSN: 0004476997 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022071099A (ja) * 2016-11-02 2022-05-13 アログ・ファーマシューティカルズ・インコーポレイテッド Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP7536320B2 (ja) 2016-11-02 2024-08-20 アログ・ファーマシューティカルズ・インコーポレイテッド Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
JP2023536068A (ja) * 2020-07-20 2023-08-23 アログ・ファーマシューティカルズ・インコーポレイテッド クレノラニブの結晶形態およびそれを用いる方法
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Also Published As

Publication number Publication date
EP3359155A4 (en) 2019-05-22
JP2022071099A (ja) 2022-05-13
HK1257195A1 (zh) 2019-10-18
WO2018085292A1 (en) 2018-05-11
MX2019005008A (es) 2019-09-10
CN108778276A (zh) 2018-11-09
IL266303A (en) 2019-06-30
CL2019001208A1 (es) 2019-07-26
JP7536320B2 (ja) 2024-08-20
CO2019005466A2 (es) 2019-07-31
EA201991078A1 (ru) 2019-11-29
US11078541B2 (en) 2021-08-03
PH12019500965A1 (en) 2019-12-02
US12404555B2 (en) 2025-09-02
AU2017353925A1 (en) 2018-09-27
BR112019008762A2 (pt) 2019-07-16
US20250305063A1 (en) 2025-10-02
KR20180074792A (ko) 2018-07-03
ZA201903089B (en) 2019-12-18
SG11201903889TA (en) 2019-05-30
KR20200079351A (ko) 2020-07-02
US20210324481A1 (en) 2021-10-21
CA3024012A1 (en) 2018-05-11
JP2024096859A (ja) 2024-07-17
EP3359155A1 (en) 2018-08-15
PE20191238A1 (es) 2019-09-11
US20180117031A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
JP7536320B2 (ja) Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
US12171757B2 (en) Crenolanib for treating FLT3 mutated proliferative disorders
US10463658B2 (en) Method of inhibiting FLT3 kinase
JP2026515176A (ja) Ｔｋｉ耐性及びｓｄｈ欠損型ｇｉｓｔを治療する方法
US12534764B2 (en) Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US20210145823A1 (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
Goemans et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657
OA19291A (en) Crenolanib for treating FLT3 mutated proliferative disorders associated mutations.
US20220218694A1 (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
OA18036A (en) Crenolanib for treating FLT3 mutated proliferative disorders.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102